Practical Applications of the HIV Lipodystrophy Case Definition

AIDS Reader

Volumn 13, Issue 10, 2003, Pages 480-481+486

  Puls, Rebekah L ^a   Carr, Andrew ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Diagnosis; HIV AIDS; Lipodystrophy; Metabolic abnormalities, HIV associated

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABACAVIR; ANTIDIABETIC AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; CHOLESTEROL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY FAT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INSULIN RESISTANCE; LACTIC ACIDEMIA; LEUKOCYTE COUNT; LIPOATROPHY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS INFECTION; BLOOD; CASE CONTROL STUDY; CLASSIFICATION; HIV ASSOCIATED LIPODYSTROPHY; HOSPITALIZATION; METABOLISM; REVIEW;

ADULT; BODY COMPOSITION; CASE-CONTROL STUDIES; CHOLESTEROL; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; SEVERITY OF ILLNESS INDEX;

EID: 0242291158     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
2. Thiebaut R, Dequae-Merchadou L, Ekouevi DK, et al. Incidence and risk factors of severe hypertriglyceridaemia in the era of highly active antiretroviral therapy: the Aquitaine Cohort, France, 1996-99. HIV Med. 2001;2:84-88.
3. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Clin Infect Dis. 2000;31:1482-1487.
4. Maggi P, Serio G, Epifani G, et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS. 2000;14:F123-F128.
5. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001;15:1389-1398.
6. Kotler DP, Rosenbaum K, Wang J, et al. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:228-237.
7. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659-1667.
8. Carr A, Miller J, Law L, et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14:F25-F32.
9. Miller JE, Carr A, Emery S, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 2003;4:293-301.
10. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus. Lancet. 1999;353:2093-2099.
11. Carrieri P, Cailleton V, Le Moing V, et al, for the APROCO study group. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defic Syndr. 2001;28:232-239.
12. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS. 2000;14:37-49.
13. Kingsley L, Smit E, Riddler S, et al. Prevalence of lipodystrophy and metabolic abnormalities in the Multicenter AIDS Cohort Study (MACS). In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago. Abstract 538.
14. Belloso WH, Quiros RE, Ivalo SA, et al. Agreement analysis of variables involved in lipodystrophy syndrome definition in HIV-infected patients. J Acquir Immune Defic Syndr. 2003;32:104-111.
15. Martínez E, Bianchi L, García-Viejo MA, et al. Sonographic assessment of regional fat in HIV-1-infected people. Lancet. 2001;356:1412-1413.
16. Carr A, Emery S, Law M, et al, for the HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults. Lancet. 2003;361:726-735.
17. Hyams KC. Developing case definitions for symptom-based conditions: the problem of specificity. Epidemiol Rev. 1998;20:148-156.
18. Shekelle PG, Woolf SH, Eccles M, et al. Developing guidelines. BMJ. 1999;318:593-596.
19. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-1277.
20. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
21. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum. 1990; 33:160-172.
22. Holmes GP, Kaplan JE, Gantz NM, et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med. 1988;108:387-389.
23. Komaroff AL, Fagioli LR, Geiger AM, et al. An examination of the working case definition of chronic fatigue syndrome. Am J Med. 1996;100:56-64.
24. Lachenbruch PA. Some misuses of discriminant analysis. Methods Inf Med. 1977;16:255-258.
25. Carr A, Law M, for the HIV Lipodystrophy Case Definition Study Group. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr. 2003;33:571-576.
26. Grunfeld C. Basic science and metabolic disturbances. In: Program and abstracts of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract TuOr158.
27. Dubé M, Qian D, Melançon HE, et al. Prospective, 48-week, intensive metabolic and body composition study of amprenavir-based therapy (COL30309). In: Program and abstracts of the 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; October 23-25, 2001; Athens, Greece. Abstract 14.
28. Mallon PW, Miller J, Cooper DA, et al. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 2003;17:971-979.
29. Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS. 2001;15:1811-1822.
30. Ruiz L, Negredo E, Domingo P, et al, for the Spanish Lipodystrophy Group. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr. 2001;27:229-236.
31. Carr A, Workman C, Smith D, et al, for the Mitochondrial Toxicity (MITOX) Study Group. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002; 288:207-215.
32. Chaput E, Saladin R, Silvestre M, Edgar AD. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun. 2000;271:445-450.
33. Nolan JJ, Jones NP, Patwardhan R, Deacon LF. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med. 2000;17:287-294.
34. Raskin P, Rappaport EB, Cole ST, et al. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia. 2000;43:278-284.
35. Wanke C, Gerrior J, Kantaros J, et al. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS. 1999;13:2099-2103.
36. Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized, controlled trial. JAMA. 2000; 284:472-477.